BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymphocytic leukemia (CLL). Results of prospective clinical trials demonstrate the efficacy of venetoclax to salvage patients with disease progression on BTKis, but data on B...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2020-06, Vol.135 (25), p.2266-2270
Hauptverfasser:	Lin, Victor S., Lew, Thomas E., Handunnetti, Sasanka M., Blombery, Piers, Nguyen, Tamia, Westerman, David A., Kuss, Bryone J., Tam, Constantine S., Roberts, Andrew W., Seymour, John F., Anderson, Mary Ann
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Adenine - therapeutic use Agammaglobulinaemia Tyrosine Kinase - antagonists & inhibitors Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Bridged Bicyclo Compounds, Heterocyclic - pharmacology Bridged Bicyclo Compounds, Heterocyclic - therapeutic use Brief Report Clinical Trials as Topic - statistics & numerical data Disease Progression Drug Evaluation Drug Resistance, Neoplasm Female Humans Kaplan-Meier Estimate Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphoid Neoplasia Male Middle Aged Molecular Targeted Therapy Neoplasm Proteins - antagonists & inhibitors Piperidines - therapeutic use Progression-Free Survival Protein Kinase Inhibitors - therapeutic use Pyrazoles - therapeutic use Pyrimidines - therapeutic use Remission Induction Retrospective Studies Salvage Therapy Sulfonamides - pharmacology Sulfonamides - therapeutic use Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!